trastuzumab deruxtecan,tucatinib,capecitabine
daiichi sankyo,astrazeneca,seagen,roche
['destiny,breast,2', 'destiny,breast,4', 'destiny,breast,6', 'enhertu', 'breast']
 all comparison will be cross comparison from breast data destiny01- enhertu- median 6 lines of tx- pfs 16.4 months her2climb-tuca/her/xeloda- median 4 lines of tx. pfs was 7.8 months without head to head any choice is reasonable but.....
Partner physician at Cancer Specialists of North Florida , Jacksonsville. All views are my own . Not medical advice .